Brighton Jones LLC cut its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 35.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,487 shares of the company’s stock after selling 1,912 shares during the period. Brighton Jones LLC’s holdings in Novartis were worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of NVS. Dimensional Fund Advisors LP raised its holdings in Novartis by 23.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock valued at $788,626,000 after buying an additional 1,389,610 shares during the period. Janus Henderson Group PLC raised its stake in shares of Novartis by 0.6% in the first quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company’s stock valued at $248,473,000 after acquiring an additional 16,015 shares during the period. Mondrian Investment Partners LTD lifted its holdings in shares of Novartis by 40.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock worth $199,819,000 after acquiring an additional 590,830 shares during the last quarter. Magnetar Financial LLC boosted its stake in shares of Novartis by 53.7% during the 1st quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock worth $184,372,000 after purchasing an additional 666,104 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Novartis by 191.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,904,664 shares of the company’s stock valued at $202,771,000 after purchasing an additional 1,250,318 shares during the last quarter. 13.12% of the stock is owned by institutional investors.
Novartis Stock Performance
NVS stock opened at $113.80 on Friday. Novartis AG has a 1-year low of $92.19 and a 1-year high of $120.92. The business has a 50-day moving average price of $116.44 and a 200 day moving average price of $108.42. The company has a market capitalization of $232.61 billion, a P/E ratio of 15.36, a PEG ratio of 1.66 and a beta of 0.57. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72.
Wall Street Analysts Forecast Growth
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
- Five stocks we like better than Novartis
- Investing in Construction Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- Investing In Preferred Stock vs. Common Stock
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Are Growth Stocks and Investing in Them
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.